
Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the development of ONT-380, an oral HER2-specific inhibitor, for the treatment of patients with HER2-positive metastatic breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Published: July 26th 2014 | Updated: